Septerna (SEPN) Stock Price, News & Analysis

Septerna, Inc. (Nasdaq: SEPN) is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery and development. According to the company, it is pioneering a new era of GPCR-targeted therapies using its proprietary Native Complex Platform™, which is designed to enable new approaches to GPCR drug discovery and to unlock the full potential of GPCR therapies for patients with significant unmet medical needs. Septerna is advancing a pipeline of oral small molecule drug candidates across multiple therapeutic areas, including endocrinology, immunology and inflammation, metabolic diseases and additional areas, both independently and with partners.

Septerna describes its Native Complex Platform™ as an industrial-scale platform that has led to the discovery and development of a deep and diverse pipeline of oral small molecule product candidates. The company emphasizes that it has assembled a team of GPCR experts and drug developers with experience in biochemistry, structural biology and pharmacology of GPCRs, and that it was launched by drug discovery company builders and scientific leaders in these fields. This focus on GPCR biology underpins its strategy to generate differentiated small-molecule therapies targeting validated and emerging GPCR targets.

Business focus and therapeutic areas

Septerna’s discovery and development activities are centered on GPCR targets relevant to several therapeutic areas. The company states that its pipeline is initially focused on treating patients in three main areas: endocrinology, immunology and inflammation, and metabolic diseases. In addition, Septerna reports that it is advancing discovery-stage programs using its Native Complex Platform™ across multiple therapeutic areas beyond these initial focuses.

Within endocrinology, Septerna is advancing an oral small molecule parathyroid hormone 1 receptor (PTH1R) agonist program with the stated goal of providing full-day calcium control for patients with hypoparathyroidism. The company has disclosed that it selected SEP-479 as a next-generation oral PTH1R agonist development candidate for hypoparathyroidism, following preclinical studies in multiple species. According to Septerna, SEP-479 demonstrated robust, dose-dependent effects on serum calcium and endogenous parathyroid hormone levels in a preclinical study and is projected, based on preclinical data, to have a pharmacokinetic profile supportive of once-daily dosing.

In immunology and inflammation, Septerna is developing SEP-631, a selective oral small molecule Mas-related G protein-coupled receptor X2 (MRGPRX2) negative allosteric modulator (NAM). SEP-631 is being developed for chronic spontaneous urticaria (CSU) and other mast cell-driven diseases. The company has initiated a randomized, placebo-controlled Phase 1 single-ascending dose and multiple-ascending dose clinical trial of SEP-631 in healthy adult volunteers, designed to evaluate safety, tolerability, pharmacokinetics and pharmacodynamics, including an icatibant skin challenge. Septerna notes that MRGPRX2 plays an important role in mast cell activation and degranulation and that mast cells are implicated in CSU and multiple other diseases.

Septerna also highlights a TSHR NAM program, which it describes as a thyroid-stimulating hormone receptor negative allosteric modulator effort. The company states that it is progressing multiple lead compounds in this program toward development candidate selection, with the goal of delivering a potential disease-modifying oral treatment for Graves’ disease and thyroid eye disease. In addition, Septerna reports that it is advancing discovery-stage programs targeting GPCRs in other therapeutic areas, including cardiometabolic diseases through a collaboration.

Pipeline and product candidates

According to its public descriptions, Septerna’s pipeline includes named product candidates and target programs such as SEP-786 (PTH1R), SEP-631 (MRGPRX2), and programs directed at TSHR, GLP-1R, GIPR, and GCGR. These programs are part of the company’s focus on oral small molecule GPCR-targeted therapies. The company has described its pipeline as diverse and deep, reflecting multiple programs at different stages of discovery and development.

SEP-631 is specifically described as a selective oral small molecule MRGPRX2 NAM intended to inhibit mast cell activation by selectively blocking MRGPRX2. Septerna reports that in preclinical studies, SEP-631 demonstrated potent and long-lasting inhibition of MRGPRX2 and blocked mediator-induced skin extravasation in mice engineered to express the human MRGPRX2 receptor. The company positions SEP-631 as a potential convenient oral treatment option for patients with CSU and other mast cell-driven diseases.

For its PTH1R agonist efforts, Septerna has stated that its goal is to provide full-day calcium control in hypoparathyroidism patients through an oral small molecule approach. The selection of SEP-479 as a next-generation PTH1R agonist development candidate is presented by the company as an example of the output of its Native Complex Platform™ and its focus on differentiated GPCR-targeted therapies.

Collaborations and partnerships

Septerna has entered into a global collaboration and license agreement with Novo Nordisk A/S. According to the company’s disclosures, this collaboration is focused on discovering, developing and commercializing multiple potential oral small molecule therapies for obesity, type 2 diabetes, and other cardiometabolic diseases based on certain specified molecular targets. The collaboration and license agreement became effective following early termination of the applicable regulatory waiting period, and joint research and development activities are underway.

The company has also reported receiving an upfront payment and a milestone payment associated with its collaborations, including a payment from Novo Nordisk and a milestone payment from Vertex, and has stated that it expects its existing cash position and collaboration funding to support operations for an extended period. These collaboration arrangements are presented by Septerna as important sources of funding and external validation of its GPCR-focused discovery platform.

Corporate profile and listing

Septerna, Inc. is based in South San Francisco, California, as indicated in its SEC filings. The company’s common stock, with a par value of $0.001 per share, is listed on The Nasdaq Stock Market LLC under the trading symbol SEPN or on The Nasdaq Global Market, as reflected in its Form 8-K filings. Septerna describes itself as a clinical-stage biotechnology company with a world-class team of GPCR experts and drug developers and emphasizes its focus on advancing GPCR-targeted oral small molecule therapies for patients with significant unmet needs.

The company has reported corporate governance developments, such as the appointment of a veteran biotechnology leader, Keith Gottesdiener, M.D., to its board of directors and his role as chairperson of a newly formed Research and Development Committee of the Board. It has also announced internal leadership changes, including the appointment of its Chief Operating Officer to the role of President while continuing in the COO position. These governance and leadership updates are disclosed through current reports on Form 8-K and related press releases.

Capital markets and investor engagement

Septerna participates in healthcare and investor conferences, including events such as the J.P. Morgan Healthcare Conference, the Evercore Healthcare Conference, the Cantor Global Healthcare Conference, the Wells Fargo Healthcare Conference, the Guggenheim Healthcare Innovation Conference, and the Jefferies Global Healthcare Conference. The company typically provides live webcasts of its presentations and archives replays for a period of time in the investors section of its website, as described in its press releases and Form 8-K filings.

Through these events and its SEC filings, Septerna provides updates on its business progress, clinical and preclinical programs, collaborations, financial results and anticipated milestones. The company has reported holding an annual meeting of stockholders, submitting matters such as director elections and auditor ratification to a shareholder vote, and disclosing voting results in accordance with SEC requirements.

Regulatory reporting and financial disclosures

As a public company, Septerna files periodic and current reports with the U.S. Securities and Exchange Commission. The company has furnished press releases announcing its financial results and business highlights for specific quarters as exhibits to Form 8-K filings under Item 2.02. These press releases include information on revenue, research and development expenses, general and administrative expenses, net income or loss, cash, cash equivalents and marketable securities, working capital, total assets, total liabilities, additional paid-in capital, accumulated deficit and total stockholders’ equity.

Septerna also files Form 8-K reports to disclose material corporate events, including collaboration agreements, leadership appointments, board changes, investor presentations and other events described under various items of Form 8-K. These filings demonstrate the company’s obligations as an issuer with securities registered under Section 12(b) of the Exchange Act and provide investors with ongoing information about its operations and governance.